Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Guopei Luo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6582-9624; OpenAlex author ID A5032226282. Sources: ClinicalTrials.gov.

Their work

Papers
54 (first author 10, last author 7)
Trials
7 (principal investigator on 7)
Grants
0
Labs led
1
Collaborators
72
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 3 papers · 2014: 3 papers · 2015: 4 papers · 2016: 4 papers · 2017: 7 papers · 2018: 6 papers · 2019: 4 papers · 2020: 8 papers · 2021: 2 papers · 2022: 2 papers · 2023: 3 papers, 3 trials · 2024: 2 papers, 3 trials · 2025: 2 papers · 2026: 1 paper, 1 trial

Papers 50 of 54

  1. Glucose is a potential source of glutamate for glutamine-deprived pancreatic cancer cells with KRAS mutation Last author DOI 10.3724/abbs.2026063↗
  2. Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Tri… Co-author DOI 10.1097/sla.0000000000006681↗
  3. Smad2 Cooperating with TGIF2 Contributes to EMT and Cancer Stem Cells Properties in Pancreatic Cancer via Co-Targeting SOX2. Co-author DOI 10.7150/ijbs.102381↗
  4. Pancreatic Cancer: An Exocrine Tumor With Endocrine Characteristics. Co-author DOI 10.1097/sla.0000000000006168↗
  5. Efficacy of vitamin C on chemotherapy-related anemia in pancreatic cancer: study protocol for a randomized controlled trial. Last author DOI 10.1186/s13063-024-08345-w↗
  6. Hyperglycemia predicts adverse prognosis in advanced pancreatic cancer patients. Last author DOI 10.1007/s12020-022-03196-4↗
  7. Glutamine is a substrate for glycosylation and CA19-9 biosynthesis through hexosamine biosynthetic pathway in pancreatic cancer. Last author DOI 10.1007/s12672-023-00628-z↗
  8. Glutamine deprivation induces ferroptosis in pancreatic cancer cells. Last author DOI 10.3724/abbs.2023029↗
  9. Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41389-022-00411-9↗
  10. Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2022/7353572↗
  11. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Co-author DOI 10.1016/j.bbcan.2020.188409↗
  12. High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-021-02147-z↗
  13. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. First author DOI 10.1002/cam4.2895↗
  14. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.02.016↗
  15. HNF-1a promotes pancreatic cancer growth and apoptosis resistance via its target gene PKLR. Co-author DOI 10.1093/abbs/gmz169↗
  16. Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. Last author DOI 10.1177/1073274820915947↗
  17. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-020-00958-3↗
  18. Prognostic Value of the C-Reactive Protein/Lymphocyte Ratio in Pancreatic Cancer. First author DOI 10.1245/s10434-020-08301-3↗
  19. ASO Author Reflections: C-Reactive Protein/Lymphocyte Ratio as a Promising Marker for Predicting Survival in Pancreatic Cancer. First author DOI 10.1245/s10434-020-08335-7↗
  20. Lewis antigen‑negative pancreatic cancer: An aggressive subgroup. Co-author DOI 10.3892/ijo.2020.4989↗
  21. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cance… Co-author DOI 10.1002/cam4.2463↗
  22. Kras G12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.01.013↗
  23. Characteristics and Outcomes of Pancreatic Cancer by Histological Subtypes. Co-author DOI 10.1097/mpa.0000000000001338↗
  24. The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer. Co-author DOI 10.2147/cmar.s211363↗
  25. Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-018-2235-8↗
  26. MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.01.017↗
  27. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.08.003↗
  28. Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000001073↗
  29. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. Co-author DOI 10.1186/s13045-017-0551-7↗
  30. Long noncoding RNA SNHG1 promotes cell proliferation through PI3K/AKT signaling pathway in pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/jca.26207↗
  31. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. Co-author DOI 10.1002/ijc.30650↗
  32. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype. Co-author DOI 10.1016/j.canlet.2016.10.046↗
  33. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cance… Co-author DOI 10.1016/j.ejso.2017.07.010↗
  34. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000001741↗
  35. Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer. Co-author DOI 10.1245/s10434-016-5579-3↗
  36. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer. Co-author DOI 10.3892/ijo.2017.4032↗
  37. Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. Co-author DOI 10.3892/ol.2016.5501↗
  38. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. First author DOI 10.1016/j.pan.2016.09.007↗
  39. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Co-author DOI 10.1016/j.pan.2016.09.013↗
  40. Energy sources identify metabolic phenotypes in pancreatic cancer. Co-author DOI 10.1093/abbs/gmw097↗
  41. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. First author DOI 10.3390/ijms17071090↗
  42. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. First author DOI 10.1016/j.pan.2015.03.012↗
  43. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Co-author DOI 10.1245/s10434-014-4021-y↗
  44. Pancreatic cancer: BRCA mutation and personalized treatment. Co-author DOI 10.1586/14737140.2015.1086271↗
  45. Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. First author DOI 10.2147/dddt.s77597↗
  46. Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. First author DOI 10.1016/j.canlet.2014.01.004↗
  47. Effect of the number of positive lymph nodes and lymph node ratio on prognosis of patients after resection of pancreatic adenocarcinoma. Co-author DOI 10.1016/s1499-3872(14)60264-2↗
  48. Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. First author DOI 10.1155/2014/925845↗
  49. CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. Co-author DOI 10.1007/s11605-013-2389-9↗
  50. Intratumoral α-SMA enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic canc… Co-author DOI 10.1371/journal.pone.0071189↗

Trials 7

  1. Multicentric Database for KRAS Mutant Pancreatic Cancer Principal investigator NCT07557849↗
  2. mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Principal investigator NCT06149689↗
  3. mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy Principal investigator NCT06249321↗
  4. Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer Principal investigator NCT06250972↗
  5. Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer Principal investigator NCT06017284↗
  6. Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer Principal investigator NCT06018883↗
  7. Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer Principal investigator NCT06018896↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 50 shared papers, 2011–2025 · strength 4.24
  2. Chen Liu · 46 shared papers, 2011–2025 · strength 3.59
  3. Quanxing Ni · 32 shared papers, 2012–2026 · strength 2.91
  4. Kaizhou Jin · 32 shared papers, 2015–2025 · strength 2.64
  5. He Cheng · 22 shared papers, 2016–2022 · strength 1.96
  6. Zhiwen Xiao · 15 shared papers, 2012–2026 · strength 1.71
  7. Zhiyao Fan · 17 shared papers, 2018–2021 · strength 1.67
  8. Yitao Gong · 14 shared papers, 2019–2022 · strength 1.58
  9. Jin Xu · 23 shared papers, 2011–2025 · strength 1.33
  10. Yunzhen Qian · 10 shared papers, 2020–2022 · strength 1.14
  11. Jiang Long · 20 shared papers, 2011–2018 · strength 0.97
  12. Meng Guo · 16 shared papers, 2014–2018 · strength 0.94
  13. Chao Yang · 10 shared papers, 2018–2020 · strength 0.84
  14. Liang Liu · 15 shared papers, 2013–2018 · strength 0.74
  15. Xinzhe Zhu · 3 shared papers, 2023–2024 · strength 0.66
  16. Kun Fan · 7 shared papers, 2018–2020 · strength 0.60
  17. Cheng He · 6 shared papers, 2015–2023 · strength 0.52
  18. Zuqiang Liu · 10 shared papers, 2013–2017 · strength 0.50
  19. Xu Wang · 3 shared papers, 2022–2025 · strength 0.45
  20. Zhengjie Dai · 3 shared papers, 2022–2023 · strength 0.44
  21. Weiding Wu · 2 shared papers, 2021–2025 · strength 0.31
  22. Si Shi · 3 shared papers, 2013–2025 · strength 0.27
  23. Yesiboli Tasiheng · 2 shared papers, 2022 · strength 0.27
  24. Yusheng Chen · 2 shared papers, 2022 · strength 0.27
  25. Xuan Lin · 2 shared papers, 2022 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.